Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Aclarion, Inc.

Get SEC filing alerts via email and in your feed for Aclarion, Inc.

ACON ACONW

Aclarion, Inc.

About Aclarion, Inc.

Aclarion, Inc. develops non-invasive diagnostic technology using Magnetic Resonance Spectroscopy (MRS) and proprietary biomarkers to identify painful intervertebral discs causing chronic low back and neck pain. Its flagship product, NOCISCAN®, enhances standard MRI scans by chemically analyzing disc tissue to guide treatment decisions, primarily for spine surgeons and imaging centers. The company’s software-driven platform aims to improve patient outcomes and reduce healthcare costs in the large, costly back pain market.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Aclarion, Inc.

1
1
Aclarion, Inc. Aclarion Reports 11.3% Revenue Growth in Q1 2026, Despite Increased Net Loss

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Aclarion, Inc. Aclarion, Inc. Reports 65.6% Revenue Growth and $7.23 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Aclarion, Inc. Aclarion Reports 31.5% Revenue Growth but Incurred Net Loss in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Aclarion, Inc. Aclarion Reports 76% Revenue Growth but Net Loss in Latest Quarter

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Aclarion, Inc. Aclarion Reports Decline in Revenue and Net Loss for Q3 and Nine Months of 2024

Via official filing (AI summary) | over 1 year ago | 0 comments